Role of cetuximab in the treatment of patients with NSCLC: are we throwing out the baby with the bath water?
Floriani
Irene
I
Garassino
Marina Chiara
MC
Broggini
Massimo
M
Veronese
Silvio
S
Marsoni
Silvia
S
Marabese
Mirko
M
Farina
Gabriella
G
Scanni
Alberto
A
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000556:secondary; D000068818:Cetuximab; D019317:Evidence-Based Medicine; D005819:Genetic Markers; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D018579:Patient Selection; D011237:Predictive Value of Tests; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014408:Biomarkers, Tumor; D005819:Genetic Markers; D000068818:Cetuximab